Publications listed in Table S1 and Table S2 were obtained from a database query of SciFinder® (www.cas.org/products/scifinder) and Google Scholar® (www.scholar.google.com) on 2015-May-30 (see Figure 1a,b of the main manuscript for more details).

S1 Table: Nanoparticle tumour delivery efficiency

| Material | Hydro- dynamic diameter [nm] | Shape | Surface chemistry | Zeta potential [mV] | Tumour model and animal | Tumour stage | Number of time points (total time period, p.i.) | AUC _{Tumour} [%ID·h/g] | Tumour uptake [%ID/g] | Delivery efficiency [%ID] ^(c) | Ref. |
|----------|---------------------------------------|-----------|------------------------|---------------------------|--|------------------------------|---|---------------------------------|-----------------------------|--|------|
| Gold | 26 | AR 3.8 | PEG_5kDa | -18 | Human cervical carcinoma (HeLa) s.c. inoculated to | Volume: ~100 mm ³ | 3 | 2440.8 | 16.4 | 2.0 | 1 |
| | 38 x 10 (TEM) | Rods | 1 BS_SKBu | | flank of mice | Mass: ~0.1 g | (168 h) | | | | |
| Gold | 3 | Spherical | Glutathione- coated | -4 | Murine cervical carcinoma (U14) s.c. inoculated to right | Volume: ~110 mm³ | 8 | 378. 1 | 5.3 | 0.7 | 2 |
| | | | coateu | | shoulder of mice (*) | Mass: ~0.1 g | (72 h) | | | | |

| Gold | 6 | Spherical | Glutathione/PE G_2kDa coated; Folic acid | -5 | Human gastric cancer (MGC-803) s.c. inoculated to right flank of mice | Volume: ~175 mm³ Mass: ~0.2 g | 6 (168 h) | 1.4 | <0.1 (1E-2) | <0.1 (2E-3) | 3 |
|------|----|-----------|---|----|--|--|--------------|-------|----------------|----------------|---|
| | 42 | | PEG_5kDa and EGF peptide | -5 | | Volume ~251 mm³ | 3 | 567.8 | 3.4 | 1.0 | |
| Gold | 38 | Spherical | PEG_5kDa | -5 | Rat glioma (9L.E29) s.c. inoculated to flank of mice | Mass: ~0.3 g | (168 h) | 584.8 | 3.5 | 1.1 | 4 |
| Gold | 68 | Star | PEG_2kDa and aptamer AS1411 | -9 | Metastatic human breast cancer (MDA-MB-231) s.c. inoculated to right flank of mice | Volume: ~500 mm³ Mass: ~0.6 g | 3 (72 h) | 224.4 | 3.1 | 2.0 | 5 |
| Gold | 46 | Spherical | PEG_5kDa and PEG_10kDa- | -7 | Human melanoma (MDA-MB-435) s.c. | Volume: | 6 | 890.0 | 18.5 | 14.0 | 6 |

| | 64 | Alexa Fluor 750 | -15 | inoculated to hind flank of mice | ~630 mm³ | (48 h) | 680.0 | 14.2 | 11.0 | |
|------|-----|----------------------------------|----------|-------------------------------------|----------|--------|--------|------|------|---|
| | 104 | | -10 | | Mass: | | 520.0 | 10.8 | 8.2 | |
| | 166 | - | -6 | - | ~0.8 g | | 241.0 | 5.0 | 3.8 | |
| | 50 | | -1 | _ | | | 1200.0 | 25.0 | 18.9 | |
| | 60 | PEG_5kDa and transferrin | -11 | | | | 980.0 | 20.0 | 15.1 | |
| | 100 | PEG_10kDa- Alexa Fluor 750 | -9 | _ | | | 1010.0 | 21.0 | 15.9 | |
| | 176 | | -5 | | | | 400.0 | 8.3 | 6.3 | |
| | | | | | Volume: | | | | | |
| Gold | 7 | Spherical Human serum | Not | Human glioblastoma (U-87MG) s.c. | ~75 mm³ | 5 | 303.5 | 12.6 | 1.1 | 7 |
| Goid | 1 | albumin | reported | inoculated to front flank of mice | Mass: | (24 h) | 303.3 | 12.0 | 1.1 | |
| | | | | | ~0.1 g | | | | | |

| Gold | 27 (TEM) | Spherical | Choline and PEI | Not reported | Human prostate cancer (DU145) s.c. inoculated to flank of mice | Volume: ~300 mm³ Mass: ~0.4 g | 5 (24 h) | 4.2 | 0.2 | 0.1 | 8 |
|------|----------|----------------------|--|-------------------------------------|--|--------------------------------|-------------|-------|-----|-----|---|
| | 17 | | Trimethylamm onium and sulfonic groups | -10 | Human carcinoma | Volume: ~100 mm³ | 3 | 670.8 | 9.3 | 1.1 | |
| Gold | 31 | Spherical | PEG_2kDa | -11 | - (KB) s.c. inoculated to right rear flank of mice | Mass: ~0.1 g | (72 h) | 318.0 | 4.4 | 0.5 | 9 |
| | 18 | | PEG_2kDa | 25 | | Volume: | | 79.5 | 1.7 | 0.3 | |
| Gold | 21 | PEG_3.4kDa — Tripod | 25 | Human glioblastoma (U-87MG) s.c. | ~300 mm ³ | 4 | 98.4 | 2.1 | 0.7 | 10 | |
| Goid | 26 | - 111pod | PEG_6kDa | 22 | inoculated to right front flank or right hind flank of mice | t | | 128.7 | 2.7 | 1.0 | |
| | 24 | RGD -2 | -21 | | ~0.4 g | | 359.0 | 7.5 | 2.7 | | |

| Gold | 30 (14 x 45) TEM | AR 3.2 Rods | PEG_5kDa | ~0 | Murine colon carcinoma (CT26.wt) s.c. inoculated to flank of mice | Volume: ~120 mm³ Mass: ~0.1 g | 3 (48 h) | 15.7 | 0.3 | 0.1 | 11 |
|------|------------------------|-----------------|------------|----|--|--------------------------------|-------------|-------|------|-----|----|
| | 70 | Spherical | | | | | | 349.2 | 14.6 | 1.8 | |
| | 125 92 x7 (TEM) | Disk | - PEG_5kDa | ~0 | Murine mammary carcinoma (EMT-6) s.c. inoculated to right flank of mice | Volume: ~100 mm ³ | | 93.6 | 3.9 | 0.5 | 12 |
| Gold | 75 39 x 9 | AR 4.3 Rods | | | | Mass: ~0.1 g | | 27.5 | 1.1 | 1.1 | |
| | 125 | Cubic nanocages | | | | | | 124.9 | 5.2 | 0.6 | _ |

| Gold | 6 | Spherical | PEG_1kDa | ~0 | Human breast cancer (MCF-7) orthotopically inoculated to mammary fat pad of mice | Volume: ~180 mm³ Mass: ~0.2 g | 4 (48 h) | 275.2 | 5.7 | 1.2 | 13 |
|------|----|----------------|---|---|--|--------------------------------|--------------|-------|-----|-----|----|
| Gold | 31 | Spherical | Plasma- polymerized allylamine and cetuximab antibody | Not reported | Human epithelial carcinoma (A431) s.c. inoculated to flank of mice | Volume: ~300 mm³ Mass: ~0.4 g | 6 (168 h) | 618.2 | 3.7 | 1.3 | 14 |
| | 96 | | PEG_5kDa | 19 | Murine mammary | Volume: ~290 mm³ | 3 | 31.0 | 1.3 | 0.5 | |
| Gold | 64 | Cubic PEG_5kDa | 10 | carcinoma (EMT-6) s.c. inoculated to hind flank of mice | Mass: ~0.4g | (24 h) | 167.4 | 7.0 | 2.4 | 15 | |

| | 60 | | PEG_5kDa | -11 | | Volume: | | 2.5 | 0.1 | <0.1 (3E-2) | |
|------|------------------|-------------|----------------------------|--------------------------|--|----------------------|--------|-------|------|----------------|----|
| Gold | 72 | _ Spherical | PEG_5kDa and TNF-α protein | -3 | Human prostate cancer (LNCaP) s.c. | ~270 mm ³ | 3 | 52.5 | 2.2 | 0.7 | 16 |
| | 67 | | PEG_5kDa | -3 | inoculated to hind limb of mice | Mass: ~0.3g | (24h) | 61.1 | 2.6 | 0.8 | |
| | 63 | | Carboxy- PEG_5kDa | -27 | | | | 57.2 | 2.4 | 0.8 | |
| Gold | 63 | Spherical | PEG_5kDa | Not reported (neutral ZP | Lymphoblastoid (LCL) tumour cells s.c. inoculated to | Volume: ~63 mm³ | 4 | 727.2 | 15.2 | 0.2 | 17 |
| | | | | is assumed) | right flanks of mice | Mass: ~75mg | (48 h) | | | | |
| Gold | 61 x 15 (TEM) | AR 4.0 | PEG_5kDa and RGDfK | -44 | Human prostate cancer (DU145) s.c. inoculated | Volume: ~75 mm³ per | 3 | 60.7 | 1.3 | 0.2 | 18 |
| | (1121/1) | Rods | peptide | | bilaterally to flank of mice | tumour (2 tumours | (48 h) | | | | |

| | | | | | | per mouse) | | | | | |
|------|------------------|----------------|----------|-----|---|----------------------------------|---------|-------|----------------|----------------|----|
| | | | PEG_5kDa | -10 | | Mass: ~0.2 g (total tumour mass) | | 342.8 | 7.1 | 1.3 | |
| | 45 x 10 (TEM) | AR 4.5 Rods | PEG_5kDa | 1 | Human ovarian cancer (A2780) orthotopically | Volume: ~1.8 cm³ | 5 | 218.6 | 1.3 | 2.7 | 10 |
| Gold | 89 | Spherical | PEG_5kDa | -27 | inoculated to left ovarian bursa of mice | Mass: ~2.1 g | (168 h) | 26.3 | 0.2 | 0.3 | 19 |
| | 22 | | PEG_2kDa | | Human melanoma | Volume: | 4 | 0.3 | <0.1 (1E-2) | <0.1 (1E-2) | |
| Gold | 40 | Spherical | PEG_2kDa | ~0 | (MDA-MB-435) orthotopically inoculated to back of mice | Mass: | (24 h) | 15.8 | 0.7 | 0.8 | 20 |
| | 61 | | PEG_5kDa | | | ~1.2 g | | 26.5 | 1.1 | 1.3 | |

| | 83 | | PEG_10kDa | | | | | 20.4 | 0.9 | 1.0 | |
|---|-------------|-----------|--|-----------------|---|--------------------------------|-------------|-------|-----|-----|----|
| | 99 | - | PEG_10kDa | | | | | 17.9 | 0.8 | 0.9 | |
| Gold iron oxide heterostructur e | 24 | Spherical | PEG_2kDa and anti-EGFR small Affibody protein | -29 | Human epithelical carcinoma (A431) subcutaneously inoculated to right shoulders of mice | Volume: ~220 mm³ Mass: ~0.3 g | 5 (48 h) | 179.2 | 3.7 | 1.0 | 21 |
| Iron oxide | (16) TEM | Spherical | Silica coating, PEG, Trastuzumab antibody | Not reported | Human breast cancer (SkBr3) s.c. inoculated to flank of mice | Volume: ~65 mm³ Mass: ~0.1 g | 3 (48 h) | 421.8 | 8.8 | 0.7 | 22 |

| Iron oxide | 140 | Spherical | Starch shell modified with PEG_1kDa and PSMA antigen | -12 | PSMA+ PIP and PSMA- flu s.c. inoculated to opposite front flanks of mice | Volume: ~140 mm³ Mass: ~0.2 g | 5 (96 h) | 275.5 | 2.9 | 0.5 | ²³ (+) |
|------------|-----|-------------|---|-----|--|--------------------------------|-------------|-------|-----|----------------|-------------------|
| Iron oxide | 161 | Spherical | Biotin | -6 | Human glioblastoma (U-87MG) s.c. inoculated to right thigh of mice | Volume: ~130 mm³ Mass: ~0.2 g | 4 (24h) | 14.4 | 0.6 | 0.1 | 24 |
| | 49 | | Dextran | -7 | Human nasopharyngeal | Volume: ~1.6 cm ³ | 3 | 4.1 | 0.2 | <0.1 (3E-2) | - 0.5 |
| Iron oxide | 54 | Spherical F | Folic acid | -9 | epidermal carcinoma (KB) s.c. inoculated to right hind leg of mice | Mass: ~1.9 g | (24h) | 13.4 | 0.6 | 0.1 | 25 |

| | 68 | | PEG_5kDa | Not reported | Human glioblastoma | Volume: ~180 mm³ | 5 | 123.4 | 2.6 | 0.6 | |
|------------|--------------|-----------|---------------------------------|-----------------|---|--------------------------------|-------------|-------|-----|-----|----|
| Iron oxide | Not reported | Spherical | PEG_5kDa and cRGD peptide | Not reported | (U-87MG) s.c. inoculated to front flank of mice | Mass: ~0.2 g | (48 h) | 258.3 | 5.4 | 1.2 | 26 |
| Iron oxide | 51 | Spherical | Human serum albumin | Not reported | Murine breast cancer (4T1) s.c. inoculated to right flank of mice | Volume: ~500 mm³ Mass: ~0.6 g | 3 (24 h) | 48.9 | 2.0 | 1.2 | 27 |
| | 226 | | PEG_5kDa- cRGDyK- peptide | -4 | Human glioblastoma - (U-87MG) s.c. | Volume: ~125 mm³ | 4 | 108.9 | 6.1 | 1.3 | |
| Silica | 220 | Spherical | PEG_5kDa | -4 | inoculated to front flank of mice | Mass: ~0.2 g | (18 h) | 63.5 | 3.5 | 0.8 | 28 |

| Silica | 75 | Spherical | Polypyrrole | -10 | Murine breast cancer (4T1) s.c. inoculated to right rear flank of mice | Volume: ~65 mm³ Mass: ~0.1 g | 3 (24 h) | 116.6 | 4.9 | 0.4 | 29 |
|--------|-----|-----------|----------------------------------|-----|--|-------------------------------|-------------|-------|-----|-----|----|
| | 125 | | PEG_5kDa- Maleimide | -11 | Human glioblastoma | Volume: ~70 mm³ | 4 | 49.6 | 2.3 | 0.2 | |
| Silica | 129 | Spherical | PEG_5kDa and VEGF ₁₂₁ | -10 | (U-87MG) s.c. inoculated to front flank of mice | Mass: ~0.1 g | (22 h) | 138.5 | 6.3 | 0.4 | 30 |
| | 190 | | PEG_5kDa- Maleimide | -5 | Murine breast cancer | Volume: ~144 mm³ | 4 | 72.2 | 3.0 | 0.5 | |
| Silica | 194 | Spherical | PEG_5kDa and TRC105 | -4 | Murine breast cancer (4T1) s.c. inoculated to front flank of mice | Mass: ~0.2 g | (24 h) | 182.7 | 7.6 | 1.4 | 31 |

| | Not reported | | PEG_5kDa | Not reported | Murine breast cancer | Volume: ~144 mm³ | 5 | 95.8 | 2.0 | 0.3 | |
|--------|--------------|-----------|-------------------------------------|-----------------|--|---------------------|-------------|-------|-----|-----|----|
| Silica | 175 | Spherical | PEG_5kDa and TRC105(Fab) | -3 | (4T1) s.c. inoculated to front flank of mice | Mass: ~0.2 g | (48 h) | 193.9 | 4.0 | 0.7 | 32 |
| Silica | 7 | Suboviced | PEG_0.5kDa | ~0 | Human melanoma (M21) s.c. | Volume: ~200 mm³ | 3 (96 h) | 33 | 0.3 | 0.1 | 33 |
| Silica | 7 | Spherical | PEG_0.5kDa and cRGDY peptide | -3 | inoculated to hind legs of mice | Mass: ~0.2 g | 5 (168 h) | 127.8 | 0.8 | 0.2 | |
| | 168 | | PEG_10kDa and TRC105 antibody | -3 | Murine breast cancer | Volume: ~140 mm³ | 6 | 220.6 | 4.6 | 0.8 | |
| Silica | 142 | Spherical | PEG_5kDa | 1 | (4T1) s.c. inoculated to front flank of mice | Mass: ~0.2 g | (48 h) | 118.3 | 2.5 | 0.4 | 34 |

| | 42 | AR 1.4 Rods | Silica and PEG_2kDa | ~0 | | | | 86.3 | 1.2 | 0.7 | |
|---|-----|----------------|----------------------------------|-----|---|---------------------|--------|-------|-----|-----|----|
| Silica-coated | 44 | AR 1.4 Rods | Silica , PEG_2kDa, and BSA | -14 | Murine breast cancer (4T1) s.c. inoculated | Volume: ~500 mm³ | 3 | 44.5 | 0.6 | 0.4 | 35 |
| gold — | 20 | AR 4.0 Rods | BSA | -20 | to right hind leg of mice | Mass: ~0.6 g | (72 h) | 28.0 | 0.4 | 0.2 | |
| | 7 | Spherical | BSA | -24 | | | | 57.5 | 0.8 | 0.5 | |
| CuS nanoparticles | 155 | | PEG_5kDa- TRC105 | -3 | Murine breast cancer (4T1) s.c. inoculated to front flank of mice | Volume: ~144 mm³ | 3 | 120.8 | 5.0 | 0.9 | |
| encapsulated in mesoporous silica shells | 155 | Spherical | PEG_5kDa | -3 | | Mass: ~0.2 g | (24 h) | 24.4 | 1.0 | 0.2 | 36 |

| Silica-coated Mn ₃ O ₄ | 53 | Spherical | PEG_3kDa and AS411 aptamer | -12 | Human cervical carcinoma (HeLa) s.c. inoculated to left flank of mice | Volume: ~700 mm³ Mass: ~0.8 g | 4 (24 h) | 105.4 | 4.4 | 3.7 | 37 |
|--|-----|-----------|------------------------------------|-----------------|--|--------------------------------|--------------|-------|-----|-----|----|
| NaGdF ₄ | 32 | Spherical | PEG_2kDa and (cRGDyk) ₂ | Not reported | Human glioblastoma (U-87MG) s.c. inoculated to right shoulder region of mice | Volume: ~1.8 cm³ Mass: ~2.1 g | 3 (22 h) | 43.6 | 2.0 | 4.2 | 38 |
| MoS ₂ /Fe ₃ O ₄ | 190 | Flake | PEG_0.4kDa | -22 | Human pancreatic carcinoma (PANC-1) s.c. inoculated to backside of mice | Volume: ~100 mm³ Mass: ~0.1 g | 5 (168 h) | 308.8 | 1.8 | 0.2 | 39 |

| Bi ₂ Se ₃ | 60 | Plate | Poly(vinylpyrr olidine) | -17 | Murine cervical carcinoma (U14) s.c. inoculated to right shoulder of mice (*) | Volume: ~115 mm³ Mass: ~0.1 g | 7 (72 h) | 420.2 | 5.8 | 0.8 | 40 |
|---------------------------------|-----|-----------|-------------------------------|-----|--|--------------------------------|-------------|-------|------|-----|----|
| Calcium phosphate | 80 | Spherical | PEG_12kDa- <i>b</i> - PAsp | ~0 | Murine colon adeno- carcinoma (C-26) s.c. inoculated in mice | Volume: ~100 mm³ Mass: ~0.1 g | 4 (24 h) | 74.2 | 3.1 | 0.4 | 41 |
| MnO | 100 | Spherical | PEG_2kDa and cRGD peptide | 3 | Human adenocarcinomic alveolar basal epithelial (A549) s.c. inoculated to right flank of mice | Volume: ~65 mm³ Mass: ~0.1 g | 3 (4 h) | 183.1 | 45.8 | 3.6 | 42 |

| | 101 | | PEG_5kDa- TRC105 | -11 | Murine breast cancer | Volume: ~180 mm³ | 4 | 128.1 | 5.3 | 1.2 | |
|------------------------|-----|-----------|-----------------------|-----------------|--|---------------------|--------|-------|-----|-----|----|
| Zinc oxide | 83 | Spherical | PEG_5kDa | -27 | (4T1) s.c. inoculated to front flank of mice | Mass: ~0.2 g | (24 h) | 50.3 | 2.1 | 0.5 | 43 |
| | | | DOTA-VEGF protein | | Human glioblastoma | Volume: ~350 mm³ | 4 | 79.8 | 3.3 | 1.4 | |
| Quantum dots | 23 | Spherical | DOTA | Not reported | (U-87MG) s.c. inoculated to front flank of mice | Mass: ~0.4 g | (24) | 17.0 | 0.7 | 0.3 | 44 |
| | ~20 | | DOTA, PEG, and RGD | Not reported | Human glioblastoma | Volume: ~350 mm³ | 4 | 73.7 | 3.0 | 1.2 | |
| Quantum dots | ~20 | Spherical | DOTA, PEG | Not reported | (U-87MG) s.c. inoculated to left front flank of mice | Mass: ~0.4 g | (25 h) | 12.5 | 0.5 | 0.4 | 45 |
| Quantum dot – liposome | 39 | Spherical | PEG_2kDa- COOH | -8 | Murine skin melanoma (B16-F10) s.c. | Volume: | 3 | 225.5 | 3.1 | 0.9 | 46 |

| hybrids | 113 | _ | DOPC:Chol:D OTAP | 54 | inoculated to right flank of mice | ~250 mm³ | (72 h) | 89.9 | 1.3 | 0.4 | |
|----------------------------------|---------------------------|-----------|---------------------------------|-----------------|---|--------------------------------|-------------|-------|-----|----------------|----|
| | 108 | _ | DOPC:Chol:D SPE- PEG_2kDa | -28 | - | Mass: ~0.3 g | | 145.2 | 2.0 | 0.6 | |
| | 110 | | DSPC:Chol:DS PE-PEG_2kDa | -25 | | | | 274.2 | 3.8 | 1.1 | |
| Hydrogel iron oxide hybrid | 20 (core size; TEM) | Spherical | DOTA, PEG, and ChL6 mAb | Not reported | Human breast adenocarcinoma (HBT3477) s.c. inoculated on both sides of the abdomen of mice | Volume: ~238 mm³ Mass: ~0.3 g | 4 (96 h) | 829.2 | 8.6 | 2.5 | 47 |
| Polymeric | 37 | Spherical | PLG160-g- PEG_5kDa | -9 | Lewis lung carcinoma (LLC) s.c. inoculated to right flank of mice | Volume: ~170 mm³ Mass: ~0.2 g | 5 (48 h) | 1.3 | 0.1 | <0.1 (1E-2) | 48 |

| _ | 71 | | Hydrazine, PEG_2kDa and folic acid | 4 | | Volume: | | 250.9 | 10.5 | 0.6 | |
|---------------|-----|----------------|---|-----|---|---------------------|-------------|-------|----------------|----------------|----|
| Polymeric | 87 | Spherical | Carbamate, PEG_2kDa and folic acid | 2 | Murine breast cancer (4T1) s.c. inoculated to right back of mice | ~50 mm³ Mass: | 5 (24 h) | 195.7 | 8.2 | 0.5 | 49 |
| _ | 64 | | mPECL | 3 | _ | ~0.06 g | | 92.5 | 3.9 | 0.2 | |
| | 72 | | Cy7-labeled mPEG_5kDa- <i>b</i> -p-(HPMAm- Bz) | -1 | Human epidermoid carcinoma (A431) | Volume: ~144 mm³ | 4 | 551.9 | 11.5 | 2.0 | 50 |
| Polymeric — | 72 | Spherical | Cy7-labeled mPEG_5kDa- b-p-(HPMAm- Bz) and Cy5.5 model drug | -1 | s.c. inoculated to right flank of mice | Mass: ~0.2 g | (48 h) | 464.0 | 9.7 | 1.7 | 30 |
| Polymeric | 268 | AR 4.0 Rods | PEG_5Da | -37 | Non-small cell lung (A549-luc) orthotopically inoculated in mice | Volume: ~200 mm³ | 6 | 2.7 | <0.1 (4E-2) | <0.1 (1E-3) | 51 |

| | | | | | Human ovarian adenocarcinoma (SKOV-3) s.c. inoculated to left flank of mice | Mass: ~0.2 g | (72 h) | 4.0 | <0.1 (1E-2) | <0.1 (2E-3) | |
|-----------|-----|-----------|-------------------------|-----|---|---------------------|--------|------|----------------|----------------|----|
| Polymeric | 22 | Spherical | Pluronic P105, | -1 | Human breast cancer (MCF-7/ADR) s.c. | Volume: ~270 mm³ | 7 | 28.7 | 0.6 | 0.1 | 52 |
| Polymeric | 22 | Spherical | F127 | • | inoculated to right hind leg of mice | Mass: ~0.3 g | (48) | 20.7 | 0.0 | 0.1 | |
| | 165 | _ | PTC-b-PGA (vesicle) | -28 | Human renal | Volume: ~175 mm³ | 6 | 20.1 | 0.8 | 0.2 | |
| Polymeric | 164 | Spherical | PEG-b-PBLG (micelle) | -6 | carcinoma (MRI- H-121) s.c. inoculated in mice | Mass: ~0.2 g | (24 h) | 18.0 | 0.8 | 0.2 | 53 |

| Polymeric | 124 | Spherical | Poly-γ- glutamic acid and folic acid | -28 | Hepatocellular carcinoma (HeDe) implanted to left kidney of rats | Volume: ~1.2 cm³ Mass: ~1.2 g | 4 (24 h) | 22.6 | 0.9 | 1.1 | 54 |
|-----------|-----|----------------|---|-----|---|--------------------------------|-------------|-------|----------------|----------------|------|
| | 62 | | PEG_2kDa | -22 | Human epidermoid | Volume: ~30 mm³ | 3 | 0.1 | <0.1 (1E-2) | <0.1 (2E-4) | |
| Polymeric | 100 | Spherical 0 | PEG_2kDa and C225 cetuximab antibody | -30 | carcinoma (A431) s.c. inoculated in mice | Mass: ~0.04 g | (8 h) | 0.1 | <0.1 (2E-2) | <0.1 (1E-3) | - 55 |
| | 227 | AR 4.0 Rods | PLGA | -3 | Human ovarian adenocarcinoma | Volume: ~150 mm³ | 6 | 257.2 | 1.5 | 0.3 | - 56 |
| Polymeric | 263 | Cubic | PLGA | -3 | (SKOV-3) s.c. inoculated to right flank of mice | Mass: ~0.2 g | (168 h) | 297.1 | 1.8 | 0.3 | 30 |

| | 216 | AR 4.0 Rods | PLGA 20% docetaxel | -3 | Human adenocarcinomic — alveolar basal | Volume: ~150 mm³ | 6 | 43.2 | 0.3 | 0.1 | |
|-------------|-----|----------------|--|-----|--|------------------------------|---------|-------|----------------|----------------|------|
| Polymeric | 216 | AR 4.0 Rods | PLGA 9% docetaxel | -3 | epithelial (A549) s.c. inoculated to right flank of mice | Mass: ~0.2 g | (168 h) | 60.0 | 0.4 | 0.1 | 57 |
| _ | 274 | _ | PEG_2kDa and folic acid | -12 | Metastatic human breast cancer | Volume: ~180 mm³ | 6 | 0.7 | 0.1 | <0.1 (1E-2) | - 58 |
| Polymeric | 217 | Spherical | PLGA | -14 | (MDA-MB-231) s.c. inoculated to right flank of mice | Mass: ~0.2 g | (12 h) | 0.2 | <0.1 (2E-2) | <0.1 (4E-3) | 58 |
| Polymeric - | 30 | Subarical | DACHPt- loaded micelles PEG-b-P(Glu) — | -2 | Human pancreatic adenocarcinoma — (BxPC3) s.c. | Volume: ~100 mm ³ | 3 | 173.8 | 7.2 | 0.9 | - 59 |
| r orymenc | 69 | Spherical | copolymer and P(Glu) homopolymer | -1 | inoculated in mice (TGF-β treated) | Mass: ~0.1 g | (24 h) | 138.0 | 5.8 | 0.7 | |

| | 30 | | | -2 | Murine colon adeno- carcinoma (C-26) s.c. inoculated in mice | | | 161.1 | 6.7 | 0.8 | |
|-----------|----|-----------|--|----|---|------------------|--------|-------|-----|-----|----|
| | 30 | | | -2 | Human pancreatic adenocarcinoma (BxPC3) s.c. inoculated in mice | | | 197.3 | 8.2 | 1.0 | |
| Polymeric | 54 | Spherical | DACHPt- loaded micelles PEG-b-P(Glu) | -2 | Murine colon adeno- carcinoma (C-26) s.c. inoculated in mice | Volume: ~100 mm³ | 4 | 163.9 | 6.8 | 0.8 | 59 |
| rolymenc | 54 | Sphericar | copolymer and P(Glu) homopolymer | -2 | Human pancreatic adenocarcinoma (BxPC3) s.c. inoculated in mice | Mass: ~0.1 g | (24 h) | 125.5 | 5.2 | 0.6 | |
| | 69 | | | -1 | Murine colon adeno- carcinoma (C-26) s.c. inoculated in mice | | | 182.0 | 7.6 | 0.9 | |
| | 07 | | | -1 | Human pancreatic adenocarcinoma (BxPC3) s.c. inoculated in mice | | | 77.8 | 3.2 | 0.4 | |

| | 110 | | | 0 | Murine colon adeno- carcinoma (C-26) s.c. inoculated in mice | | | 137.7 | 5.7 | 0.7 | | | |
|-------------|-----|---------------|--|-----------------|---|---------------------|-----------------------------|------------------|-----|------|------|-----|--|
| | 110 | | | ~0 | Human pancreatic adenocarcinoma (BxPC3) s.c. inoculated in mice | | | 76.6 | 3.2 | 0.4 | | | |
| | 37 | | PEG_5kDa and TRC105 | Not reported | Murine breast cancer | Volume: ~180 mm³ | 6 | 203.6 | 4.2 | 0.9 | | | |
| Polymeric | 37 | Spherical PEG | PEG_5kDa | Not reported | | Mass: ~0.2 g | (48 h) | 109.8 | 2.3 | 0.5 | 60 | | |
| | 89 | 89 | | | Crosslinked, PEG_10kDa, and tyrosine | 0 | Murine colon adenocarcinoma | Volume: ~100 mm³ | 5 | 65.2 | 2.7 | 0.3 | |
| Polymeric - | 87 | Spherical | Non- crosslinked, PEG_10kDa, and tyrosine | -1 | (C-26) s.c. inoculated to back of mice | Mass: ~0.1 g | (24 h) | 41.1 | 1.7 | 0.2 | - 61 | | |

| | 64 | | PEG | ~0 | | | | 132.7 | 5.5 | 0.6 | |
|-------------|----|-------------|-------------------------|----|--------------------------------------|------------------------------|--------|-------|-----|-----|------|
| - | 68 | _ | PEG and 5% folic acid | -1 | _ | | | 117.1 | 4.9 | 0.5 | - |
| | 69 | _ | PEG and 10% folic acid | -2 | Human carcinoma (KB) transplanted to | Volume: ~100 mm ³ | 6 | 143.6 | 6.0 | 0.6 | 62 |
| Polymeric — | 73 | Spherical — | PEG and 25% folic acid | -2 | abdominal region of mice | Mass: (24 h ~0.1 g | (24 h | 135.5 | 5.6 | 0.6 | - v2 |
| | 77 | | PEG and 50% folic acid | -7 | | ~0.1 g | . 6 | 155.1 | 6.5 | 0.7 | - |
| | 91 | _ | PEG and 100% folic acid | -9 | _ | | | 147.9 | 6.2 | 0.6 | - |
| | 35 | Spherical | PEG_12kDa | -2 | Murine colon | Volume: ~167 mm³ | 6 | 591.9 | 8.2 | 1.6 | 63 |
| | 35 | Spherical | .l PEG_12kDa -2 | | inoculated in mice | Mass: ~0.2 g | (72 h) | | | | |

| Polymeric | 23 | Spherical | PEG_0.4kDa and cRGD | Not reported (neutral ZP is assumed) | Metastatic mammary clone-66 (Cl-66) inoculated to mammary fat pad of mice | Volume: ~0.625 mm³ Mass: ~0.8 g | 5 (120 h) | 717.5 | 6.0 | 4.5 | 64 |
|-----------|-----|-----------|------------------------------------|--|---|----------------------------------|--------------|-------|-----|-----|----|
| Polymeric | 35 | Spherical | PEG_12kDa | -2 | Murine colon adenocarcinoma (C-26) s.c. inoculated in mice | Volume: ~100 mm³ Mass: ~0.1 g | 7 (48 h) | 449.5 | 9.4 | 1.1 | 65 |
| Polymeric | 208 | Spherical | PLGA and PbAE (PTX containg) | -27 | Athymic nu/nu female mice Human breast cancer (MCF-7) orthotopically inoculated to mammary fat pad of mice | Volume: ~140 mm³ Mass: | 4 (12 h) | 6.0 | 0.5 | 0.1 | 66 |

| | | | | | Human breast cancer (MCF-7 _{TR}) orthotopically inoculated to mammary fat pad of mice | ~0.2 g | | 3.3 | 0.3 | 0.1 | |
|-----------|-----|-----------|--------------------------------|-----------------|---|---------------------|--------|-------|-----|-----|----|
| | 208 | | PLGA and PbAE (CER) | -27 | Human breast cancer (MCF-7) orthotopically inoculated to mammary fat pad of mice | | | 22.5 | 1.9 | 0.4 | |
| | 200 | | containing | -21 | Human breast cancer (MCF-7 _{TR}) orthotopically inoculated to mammary fat pad of mice | | | 11.0 | 0.9 | 0.2 | |
| Polymeric | 222 | Spherical | Pyrene-ended poly(DL-lactic | Not reported | Sarcoma-180 s.c. inoculated to | Volume: ~350 mm³ | 4 | 212.2 | 4.4 | 1.9 | 67 |
| | | | acid) | теропец | axillary region of mice | Mass: ~0.4 g | (48 h) | | | | |

| | Not reported | | PEG_1.5kDa and folic acid | Not reported | Human nasopharyngeal | Volume: ~80 mm³ | 4 | 103.0 | 4.3 | 0.4 | |
|-----------|--------------|-------------|---------------------------|-----------------|--|---------------------------------|--------|-------|------|-----|----|
| Polymeric | 20 | Spherical | Poly(acrylic acid) | Not reported | epidermal carcinoma (KB) s.c. inoculated to the nape of the neck of mice | Mass: ~0.1 g | (24 h) | 132.2 | 5.5 | 0.6 | 68 |
| Polymeric | 150 | Spherical | PLGA | -16 | Ehrlich ascites tumour (EAT) intramuscularly | Volume: ~1.0 cm ³ | 4 | 19.0 | 0.8 | 1.0 | 69 |
| Tolymene | 150 | Spiromeur | 726.1 | 10 | inoculated to thigh of right hind leg of mice | Mass: ~1.2 g | (24 h) | 15.0 | 0.0 | 1.0 | |
| Polymeric | 168 | Sukariaal | RhB-CMCNP- PS | -12 | Murine hepatocellular carcinoma (H22) s.c. | Volume: ~100 mm³ | 6 | 511.6 | 21.3 | 2.6 | 70 |
| Folyment | 175 | - Spherical | RhB-CMCNP- PS | -19 | inoculated to axillary region of mice | Mass: ~0.1 g | (24 h) | 407.5 | 17.0 | 2.0 | |

| 165 | RhB-CMCNP- PS | -33 | | 375.5 | 15.6 | 1.9 | |
|-----|-------------------|-----|--------|-------|------|-----|--|
| 514 | RhB-CMCNP- PS | -21 | | 166.3 | 6.9 | 0.8 | |
| 150 | RhB-CMCNP- CPT | 15 | | 93.0 | 3.9 | 0.5 | |
| 151 | RhB-CMCNP- CPT | 26 | | 141.6 | 5.9 | 0.7 | |
| 153 | RhB-CMCNP- CPT | 35 | - - | 188.7 | 7.9 | 0.9 | |

| | 301 | | RhB-CMCNP- CPT | 24 | | | | 84.8 | 3.5 | 0.4 | |
|-------------------|-----|-----------|----------------------------------|----|---|------------------------------|-------------|-------|-----|-----|------|
| Polymeric | 40 | Spherical | PEG- <i>b</i> -P(Glu) 12-40 | -4 | Murine colon adeno- carcinoma (C-26) s.c. inoculated in mice | Volume: ~100 mm³ Mass: | 6 (72 h) | 562.1 | 7.8 | 0.9 | 71 |
| | | | | | | ~0.1 g | | | | | |
| - | 399 | - | PEI_25kDa | 38 | Ehrlich ascites tumour (EAT) s.c. | Volume: ~1.8 cm ³ | 4 | 6.9 | 0.3 | 0.6 | - 72 |
| Polymeric | 276 | Spherical | Chondroitin sulfate-PEI | 16 | inoculated to hind left flank of mice | Mass: ~2.1 g | (24 h) | 36.5 | 1.5 | 3.2 | 72 |
| Graphene oxide | 37 | Flake | NOTA, PEG_5kDa, and TRC105 | -2 | Murine breast cancer (4T1) s.c. inoculated to front flank of | Volume: | 6 | 224.4 | 4.7 | 1.0 | 73 |

| | | | 1 | | mice | ~180 mm ³ | | | | | _ |
|-------------------|-----------------------|-------|-----------------------------------|-----|--|--------------------------------|-------------|-------|-----|-----|----|
| | 26 | | NOTA, PEG_5kDa | -16 | | Mass: ~0.2 g | (48 h) | 104.2 | 2.2 | 0.5 | |
| | 22 | _ | NOTA, PEG_10kDa | -9 | Murine breast cancer | Volume: ~180 mm³ | 5 | 104.2 | 2.2 | 0.5 | |
| Graphene oxide | 27 | Flake | NOTA, PEG_10kDa, and TRC105 | ~0 | (4T1) s.c. inoculated to front flank of mice | Mass: ~0.2 g | (48 h) | 200.9 | 4.2 | 0.9 | 74 |
| Graphene oxide | 90 50 x 2 (AFM) | Flake | PEG_4kDa | -30 | Murine melanoma (B16) s.c. inoculated to right arm of mice | Volume: ~200 mm³ Mass: ~0.2 g | 6 (24 h) | 224.5 | 9.4 | 2.2 | 75 |
| Graphene oxide | 28 | Flake | PEG_5kDa | -10 | Human glioblastoma (U-87MG) s.c. inoculated to flank | Volume: | 6 | 143.1 | 3.0 | 0.2 | 76 |

| | | | _ | | of mice | ~65 mm³ | | | | | |
|---------------------|------------|-------|-----------------------------------|----------|--|---------------------|--------|-------|------|-----|------|
| | 33 | | PEG_5kDa and VEGEF ₁₂₁ | -5 | | Mass: ~0.1 g | (48 h) | 244.9 | 5.1 | 0.4 | |
| | 27 | | NOTA- TRC105 antibody | ~0 | Murine breast cancer - (4T1) s.c. inoculated | Volume: ~140 mm³ | 4 | 117.9 | 4.9 | 0.9 | |
| Graphene | 22 | Flake | NOTA | -10 | to front flank of mice | Mass: ~0.2 g | (24 h) | 77.4 | 3.2 | 0.6 | 77 |
| | | | PEG_2kDa | | | | | 63.1 | 2.6 | 0.8 | |
| Single-walled | 200 nm x | AR 67 | PEG_2kDa and RGD peptide | Not | Human glioblastoma (U-87MG) s.c. | Volume: ~250 mm³ | 5 | 89.7 | 3.7 | 1.1 | - 78 |
| carbon nanotubes | 3 nm (AFM) | Rods | PEG_5.4kDa | reported | inoculated to left front legs | Mass: | (24 h) | 100.5 | 4.2 | 1.3 | 78 |
| | | | PEG_5.4kDa and RGD peptide | | | ~0.3 g | | 290.4 | 12.1 | 3.6 | |

| Liposomes | 96 | Spherical | DPPC, cholesterol, DSPE- PEG_2kDa, Iohexol, GH680 | -60 | Human cervical carcinoma (ME180) orthotopically inoculated in mice | Volume: ~500 mm³ Mass: ~0.6 g | 10 (120 h) | 376.8 | 3.14 | 1.9 | 79 |
|-----------|-----|-----------|--|-----|---|--------------------------------|---------------|-------|------|-----|----|
| | 70 | | | | GEMMs of strain of FVB/n mice carrying a transgene for C3(1)S40 T- antigen (C3-TAg) | Volume: ~80 mm³ Mass: ~0.1 g | 9 | 400.0 | 4.2 | 0.4 | 80 |
| Liposomes | 79 | Spherical | PEG_2kDa | -36 | Tumours derived from BALB/c TP53- /- transplanted into inguinal mammary fat pad of mice | Volume: ~65 mm³ Mass: ~0.1 g | (96 h) | 175.0 | 1.8 | 0.2 | _ |
| Liposomes | 102 | Spherical | PEG_2kDa and SCL | -23 | Murine breast cancer (4T1) s.c. inoculated | Volume: | 3 | 449.1 | 9.4 | 2.3 | 81 |

| | | | | | in mice | ~200 mm³ | | | | | |
|-----------|-----|-----------|--|-----|---|--------------------------------|-------------|-------|-----|-----|----|
| | 103 | | PEG_2kDa and CLL | -13 | | Mass: ~0.3g | (48 h) | 81.5 | 1.7 | 0.4 | |
| Liposomes | 386 | Spherical | Alendronate- hyaluronate graft polymer | 20 | Ehrlich ascites tumour (EAT) s.c. inoculated to hind right flank of mice | Volume: ~600 mm³ Mass: ~0.7 g | 3 (24 h) | 56.8 | 2.4 | 1.7 | 82 |
| Liposomes | 85 | Spherical | PEG | 1 | Human non-small lung cancer (H292-GT) s.c. inoculated to left hind limb of mice | Volume: ~300 mm³ Mass: ~0.4 g | 4 (48 h) | 433.0 | 9.0 | 3.3 | 83 |

| Liposomes | 120 | Spherical | DSPE- PEG_2kDa | Not reported (neutral ZP is assumed) | Syngeneic MET1 carcinomas transplanted to mammary fat pad of mice | Volume: ~180 mm³ Mass: ~0.2 g | 4 (48 h) | 218.8 | 4.6 | 1.0 | 84 |
|-----------|-----|--------------|-------------------|--|---|--------------------------------|-------------|-------|-----|-----|----|
| | 25 | | | -3 | | Volume: | | 33.5 | 1.4 | 0.2 | |
| Liposomes | 51 | Spherical | PEG_0.7kDa | -4 | Human embryonic kidney (HEK293(β ₃)) s.c. | ~116 mm³ | 3 | 19.6 | 0.8 | 0.1 | 85 |
| | 93 | | | -6 | inoculated in mice | Mass: ~0.1 g | (24 h) | 21.7 | 0.9 | 0.1 | |
| Liposomes | 85 | Spherical | PEG_2kDa | ~0 | Murine colon adeno- carcinoma (C-26) s.c. inoculated in | Volume: ~1.2 cm ³ | 6 | 352.9 | 4.9 | 6.9 | 86 |
| | 85 | 85 Spherical | PEG_2kDa | ~0 | s.c. inoculated in mice | Mass: ~1.4 g | (72 h) | | | | |

| | 102 | | PEG_2kDa (InVNBL) | Not reported | Murine colon adeno carcinoma (C-26) | Volume: ~100 mm³ | 5 | 1264.8 | 17.6 | 2.1 | | |
|------------|-----|-----------|---|--|---|-------------------------------------|--------------|---------|-------|-----|-----|------|
| Liposomes | 131 | Spherical | PEG_2kDa (ReDXRL) | Not reported | s.c. inoculated to right hind flank of mice | Mass: ~0.1 g | (72h) | 175.0 | 2.4 | 0.3 | 87 | |
| Linosomes | 225 | Spherical | PEG-nido- carborane and transferrin | Not reported | Murine colon adeno- carcinoma (C-26) | Volume: ~270 mm³ | 5 | 204.4 | 2.8 | 0.9 | 88 | |
| Liposomes1 | 168 | Spherical | PEG- <i>nido</i> - carborane | Not reported | s.c. inoculated to back of mice | Mass: ~0.3g | (72 h) | 115.5 | 1.6 | 0.5 | | |
| | | | DSPE- PEG_2kDa | Not | Human breast cancer (BT-474) s.c. | Volume: ~450 mm³ | 9 | 440.9 | 2.6 | 1.4 | | |
| Liposomes | 90 | 90 | Spherical | DSPE- PEG_2kDa and Anti-HER Mab fragments | reported | inoculated to upper back of mice | Mass: ~0.5 g | (168 h) | 477.6 | 2.8 | 1.5 | - 89 |

| Liposomes | 118 | Spherical | DSPE- PEG_2kDa | Not reported (neutral ZP is assumed) | Murine colon adeno- carcinoma (C-26) s.c. inoculated to back of mice | Volume: ~20 mm³ per tumour (3 tumours per mouse) Mass: ~0.1 g (total tumour mass) | 7 (24 h) | 181.3 | 7.6 | 0.5 | 90 |
|-----------|-----|-----------|-------------------|--|---|--|-------------|-------|-----|-----|----|
| Liposomes | 200 | Spherical | PEG_2kDa | -2 | Anaplastic thyroid carcinoma (ARO) s.c. inoculated to flank of mice | Volume: ~520 mm³ Mass: ~0.6 g | 5 (24 h) | 35.7 | 1.5 | 0.9 | 91 |

| Liposomes | 100 | Spherical | PEG | Not reported (neutral ZP is assumed) | Human melanoma (A375) s.c. inoculated to right flank of mice | Volume: ~1.3 cm³ Mass: ~1.5 g | 11 (72 h) | 79.2 | 0.5 | 0.7 | 92 |
|-----------|-----|-----------|----------|--|---|--------------------------------|--------------|-------|-----|-----|----|
| Liposomes | 113 | Spherical | PEG | ~0 | Murine colon adeno- carcinoma (C-26) intraperitoneally inoculated in mice (*) | Volume: ~120 mm³ Mass: ~0.1 g | 7 (96 h) | 136.6 | 1.4 | 0.2 | 93 |
| Liposomes | 130 | Spherical | PEG_4kDa | Not reported (neutral ZP is assumed) | Colon adeno- carcinoma (CT26) inoculated in mice | Volume: ~100 mm³ Mass: ~0.1 g | 6 (24 h) | 32.4 | 1.4 | 0.2 | 94 |

| | 85 | _ | | | Human colorectal | Volume: ~75 mm³ | 6 | 258.5 | 3.6 | 0.3 | _ |
|-----------|-----|-----------|----------|----|--|--|-------------|-------|-----|-----|----|
| Liposomes | 100 | Spherical | PEG_2kDa | ~0 | adenocarcinoma s.c. inoculated to right hind flank of mice | Mass: ~0.1 | (72 h) | 179.9 | 2.5 | 0.2 | 95 |
| Liposomes | 107 | Spherical | PEG_2kDa | ~0 | Murine colon adeno- carcinoma (C-26) s.c. inoculated to right hind flank of mice | Volume ~75 mm³ Mass: ~0.1 g | 5 (72 h) | 293.3 | 4.1 | 0.4 | 96 |
| Liposomes | 74 | Spherical | PEG_2kDa | ~0 | Murine colon adeno- carcinoma (C-26) s.c. inoculated to right hind flank of mice | Volume: ~750 mm³ Mass: ~0.9 g | 5 (72 h) | 195.0 | 2.7 | 2.4 | 97 |

| | 201 | | Hyaluronic acid and HP-β- cyclodextrin | -14 | | | | 18.9 | 0.8 | 0.1 | |
|--------------|-----|-------------|---|-----|--|-----------------|--------|------|-----|-----|------|
| Hyaluronic _ | 217 | _ | PEG_5kDa; 2 PEG per 100 sugar repeat units of hyaluronic acid | -14 | Murine breast cancer (4T1) s.c. inoculated | Volume: ~125mm³ | 4 | 19.7 | 0.8 | 0.1 | - 98 |
| hydrogel | 226 | — Spherical | PEG_5kDa; 5 PEG per 100 sugar repeat units of hyaluronic acid | -13 | to right flank of mice | Mass: ~0.2 g | (24 h) | 31.5 | 1.3 | 0.2 | 98 |
| | 242 | | PEG_5kDa; 10 PEG per 100 sugar repeat units of hyaluronic acid | -11 | | | | 24.0 | 1.0 | 0.2 | |

| Hyaluronic acid hydrogel | 50 | Spherical | Hyaluronic acid modified with methacrylic anhydride | -45 | Murine hepatocellular carcinoma (H22) s.c. inoculated to left flank of mice | Volume: ~50 mm³ Mass: ~0.1 g | 7 (72 h) | 149.8 | 2.1 | 0.1 | 99 |
|-------------------------------|-----|-----------|--|-----|---|-------------------------------|-------------|-------|-----|-----|-----|
| Heparin- based hydrogel | 80 | Spherical | Methacrylated heparin copolymerized with cystamine bisacrylamide | -30 | Murine hepatocellular carcinoma (H22) s.c. inoculated to armpit of mice | Volume: ~50 mm³ Mass: ~0.1 g | 4 (24 h) | 176.3 | 7.4 | 0.4 | 100 |
| | 154 | | Chitosan | 9 | Murine — hepatocellular | Volume: ~200 mm³ | 6 | 123.2 | 2.6 | 0.6 | |
| Chitosan hydrogel | 133 | Spherical | Chitosan and Bj-BPP-9a peptide | 9 | carcinoma (H22) s.c. inoculated to right limb of mice | Mass: ~0.2 g | (48 h) | 145.8 | 3.0 | 0.7 | 101 |

| Hyaluronic acid hydrogel | 200 | Spherical | Hyaluronic acid | -15 | Human non-small cell lung cancer (A549 ^{DDP}) s.c. inoculated to right shoulder of mice | Volume: ~200 mm³ Mass: ~0.2 g | 3 (24 h) | 14.4 | 0.6 | 0.1 | 102 |
|-----------------------------|-----|-----------|---------------------------|-----|---|--------------------------------|-------------|-------|------|-----|-----|
| | 133 | _ | Thiolated | -25 | _ | Volume: ~150 mm³ | 6 | 138.1 | 5.8 | 1.0 | |
| Gelatin hydrogel | 179 | Spherical | PEG_2kDa | -22 | Human pancreatic carcinoma (PANC-1) s.c. inoculated in mice | | | 187.4 | 7.8 | 1.4 | 103 |
| | 231 | | PEG_2kDa and EGFR peptide | -18 | | Mass: ~0.2 g | (24 h) | 322.3 | 13.4 | 2.4 | |
| Alginic acid hydrogel | 132 | Spherical | Alginic acid | -35 | Murine hepatocellular carcinoma (H22) s.c. inoculated to right limb armpit of mice | Volume: ~150 mm³ Mass: ~0.2 g | 6 (72 h) | 275.0 | 3.8 | 0.7 | 104 |

| | 230 | | Gelatin | -8 | | | | 204.2 | 4.3 | 0.4 | |
|-----------------------|-----|-----------|---|-----|---|--------------------------------|-------------|-------|------|-----|-----|
| | 329 | _ | PEG_2kDa | -8 | Human melanoma | Volume: ~100 mm³ | 7 | 668.3 | 13.9 | 1.4 | |
| Gelatin - hydrogel | 244 | Spherical | Thiolated gelatin | -9 | (MDA-MB-435) inoculated in mice | Mass: ~0.1 g | (48 h) | 495.4 | 10.3 | 1.0 | 105 |
| _ | 302 | _ | PEG_2kDa thiolated Gelatin | -7 | _ | Ç | | 642.8 | 13.4 | 1.3 | _ |
| Cellulose hydrogel | 193 | Spherical | Methacrylated carboxymethyl cellulose and cystamine bisacrylamide | -26 | Murine hepatocellular carcinoma (H22) s.c. inoculated to left flank of mice | Volume: ~100 mm³ Mass: ~0.1 g | 7 (72 h) | 141.0 | 2.0 | 0.2 | 106 |
| Dendrimers | 8 | Spherical | PAMAM-OH dendrimer | -1 | Human ovarian carcinoma (A2780) orthotopically | Volume: | 6 | 784.8 | 4.7 | 9.8 | 107 |

| | 7 | | HPMA copolymer | -1 | inoculated beneath left ovarian bursa of mice | ~1.75 cm³ Mass: ~2.1 g | (168 h) | 44.9 | 0.3 | 0.6 | |
|------------|--------------|-----------|----------------------|-----------------|--|-------------------------|---------|-------|------|-----|-----|
| | 6 | | Lysine | 20 | Murine colon adeno- | Volume: ~100 mm³ | 6 | 53.6 | 2.2 | 0.3 | |
| Dendrimers | 17 | Spherical | PEG_5kDa | -7 | carcinoma (C-26) s.c. inoculated to back of mice | Mass: ~0.1 g | (24 h) | 273.4 | 11.4 | 1.4 | 108 |
| | Not reported | | PAMAM | Not reported | - Human carcinoma | Volume: ~900 mm³ | 3 | 178.2 | 1.9 | 2.0 | |
| Dendrimers | Not reported | Spherical | PAMAM and folic acid | Not reported | (KB) s.c. inoculated to flank of mice | Mass: ~1.1 g | (96 h) | 665.2 | 6.9 | 7.5 | 109 |

| Dendrimers | 4 | Spherical | Hydroxyl- functionalized PAMAM | 5 | Gliosarcoma (9L) intracranially implanted in rats | Volume: ~110 mm³ Mass: ~0.1 g | 6 (48 h) | 4.6 | 0.1 | <0.1 (1E-2) | 110 |
|---|----|-----------|--------------------------------------|----------|---|--------------------------------|--------------|-------|-----|----------------|-----|
| Dendrimer- entrapped gold nanoparticles | 72 | Spherical | PEG_2kDa- RGD-peptide | 6 | Human glioblastoma (U-87MG) s.c. inoculated to right side of oxters of mice | Volume: ~46 mm³ Mass: ~0.1 g | 3 (120 h) | 105.0 | 0.9 | 0.1 | 111 |
| | 5 | | Amine- terminated PAMAM | Positive | | Volume: | | 475.4 | 5.0 | 3.0 | |
| Metal- dendrimer composite nanomaterials | 5 | Spherical | Carboxy- terminated PAMAM | Negative | Murine skin melanoma (B16-F10) s.c. inoculated to dorsal surface of mice | ~500 mm³ Mass: | 4 (96 h) | 289.6 | 3.0 | 1.8 | 112 |
| | 5 | | Acetylated PAMAM | Neutral | _ | ~0.6 g | | 279.5 | 2.9 | 1.8 | - |

| | 11 | | Carboxy- terminated PAMAM | Negative | | | | 44.6 | 0.5 | 0.3 | |
|-------------------------|-------------------|------------------------------|-------------------------------------|----------|--|----------------------------------|---------|-------|------|-----|-----|
| Tabacco | 95 | AR 16.7 | DEC. OLD | | Human glioblastoma (U-87MG) s.c. | Volume: ~200 mm³ | 3 | 15.0 | 0.0 | 2.1 | 113 |
| mosaic virus | 300 x 18 (TEM) | Rods | PEG_8kDa | -36 | inoculated to upper flank of mice | Mass: ~0.2 g | (72 h) | 15.2 | 0.2 | 0.1 | 112 |
| НРМА | 16 | Spherical | НРМА | -19 | Human ovarian cancer (A2780) orthotopically | Volume: ~1.75 cm ³ | 6 | 291.1 | 1.7 | 3.6 | 114 |
| copolymer | | | | · | inoculated to left ovarian bursa of mice | Mass: ~2.1 g | (168 h) | | | | |
| PEGylated 10- | 185 | AR 1.3 Rods | Poly(maleic anhydride- <i>alt</i> - | -12 | Murine breast cancer (4T1) s.c. inoculated | Volume: ~100 mm³ | 5 | 691.0 | 28.8 | 3.5 | 115 |
| hydroxycamp tothecin | 296 | 1-octadecene)- poly(ethylene | | -12 | to right shoulder of mice | Mass: | (24 h) | 555.6 | 23.2 | 2.8 | |

| | 364 | AR 3.2 Rods | | -13 | | ~0.1 g | | 474.2 | 19.8 | 2.4 | |
|------------------------------|-----|----------------|---|-----|--|---------------------|-------------|-------|--------|--------|-----|
| | 455 | AR 4.0 Rods | | -14 | | | | 412.3 | 17.2 | 2.1 | |
| | 86 | | DOPE, cholesterol, DC-cholesterol | 71 | | Volume: | | 38.0 | 1.6 | 0.1 | |
| Solid lipid nanoparticles | 135 | Spherical | PEG_5kDa | 1 | Lung cancer (H1975) s.c. inoculated to flank region of mice | ~75 mm³ Mass: | 3 (24 h) | 98.4 | 4.1 | 0.4 | 116 |
| | 160 | | PEG_5kDa and cetuximab | -1 | | ~0.1 g | | 102.2 | 4.3 | 0.4 | |
| Solid lipid nanoparticles | 387 | Spherical | Tripalmitin | -47 | Dalton's lymphoma cells s.c. inoculated to thigh of right hind | Volume: ~900 mm³ | 3 | 1.1 | <0.1 | <0.1 | 117 |
| nanoparticles | | - | · | | leg of mice | Mass: ~1.1 g | (24 h) | | (4E-2) | (5E-2) | |